Navigation Links
Tolerx Presents Preclinical Data on Novel Anti-GITR Cancer Immunotherapeutic Demonstrating Enhanced Anti-Tumor Responses
Date:4/5/2011

eutic drugs showed potent anti-tumor activity against established tumors and were efficacious across multiple classes of drugs including alkylating agents, DNA intercalators, and pyrimidine analogs.  
  • The combination of anti-GITR and gemcitabine showed anti-tumor activity against established tumors comparable to a combination consisting of anti-CTLA4 and gemcitabine.
  • The use of a triple combination (anti-GITR, anti-CTLA4, and gemcitabine) demonstrated the greatest anti-tumor results, with complete tumor regression observed in greater than 73% of mice (P<0.01).

  • A Phase 1, first-in-human, open label, dose escalation safety study of TRX518 in adults with Stage III/IV metastatic melanoma was initiated in December 2010 and is currently underway.

    About TRX518

    TRX518 is an investigational immunotherapy designed to activate GITR (glucocorticoid-induced tumor necrosis factor receptor) found on multiple types of T cells and other immune cells. GITR plays a role in directing the anti-tumor immune response via a multifaceted mechanism of action that includes activating tumor antigen-specific T effector cells, abrogating the suppression induced by T regulatory cells, and activating NK cells. In preclinical studies, TRX518 achieved its effect without compromising normal immune function, and preclinical models suggest TRX518 to have a favorable safety profile. A Phase 1 clinical study of TRX518, a first-in-class anti-GITR monoclonal antibody, has been initiated to assess the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ascending single doses in patients with malignant melanoma. TRX518 is designed to have activating and sustaining effects on T lymphocytes and other cells for enhancing the immune system's responses against cancer cells, including responses that may occur with TRX518 alone, as well as complementary responses in combination with other cancer therapies including cancer vaccines. <
    '/>"/>

    SOURCE Tolerx, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. Laureate Announces Manufacturing Agreement with Tolerx
    2. Tolerx Expands Phase 3 DEFEND Trial of Otelixizumab in Europe
    3. Tolerx Announces Amendment to Phase 3 DEFEND Protocol
    4. Tolerx Presents Otelixizumab Phase 2 Dose Optimization Data At The IDFs 20th World Diabetes Congress
    5. Tolerx Initiates Phase 1 Clinical Trial of TRX518, a First-in-Class anti-GITR Antibody for the Treatment of Cancer
    6. Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference
    7. Acologix Presents Preclinical Data on Cartilage Regeneration by AC-100 at the 30th ASBMR Annual Meeting
    8. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
    9. MedImmune Presents Data at AAP National Conference & Exhibition Demonstrating Burden of RSV Disease
    10. GeoVax Presents Data at AIDS Vaccine 2008 Conference
    11. Dendreon Presents Preclinical Data Validating Anti-Tumor Activity of D-3263, a Trp-p8 Agonist
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/28/2015)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) ... on the development of autologous cell therapies, today ... 30, 2015, corporate highlights, and near-term milestones.  The ... at www.sedar.com ,  www.edgar.com and ... expects to launch its RCS-01 treatment for aging ...
    (Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... ... opportunity for venture capital funds, investment firms and animal health companies to hear ... have raised $160 million. Several have also received licensing agreements or distribution contracts. ...
    (Date:8/27/2015)... , Aug. 27, 2015 /PRNewswire/ - Portage ... Exchange: PBT.U), and Biohaven Pharmaceutical Holding Company Limited ... a Phase I study of BHV-0223, a glutamate ... (IND) regarding BHV-0223 and recently obtained clearance from ... proceed with human testing. Portage holds 54% equity ...
    (Date:8/27/2015)... 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" or "the Company") ... June 30, 2015. Biorem,s complete second quarter financial statements and MD&A ... HIGHLIGHTS: in ,000,s except earnings per shareThree-months ended , Six -months endedJune ... 2015 , 2014 Revenue , 4,709 ... Gross profit , 1,656 , 56 , ...
    Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3
    ... , Anne , Grabner 1 , Christoph Sachse 1 , ... , 1 Cenix BioScience GmbH, 2 ... , Sets of siRNAs focused on a specific , ... greatly increase the pace of pathway analysis and functional , ...
    ... Ambion now offers a complete Gene Expression Profiling Service* ... data analysis to our Full Service offering, , ... offering includes , consultation with Ambion's team ... and comprehensive data analysis. Ambion's long history of providing innovative, , ...
    ... Assess GAPDH siRNA delivery in less time for a fraction of the , ... Analyze from one to 96 samples simultaneously , ... toxicity , Use with Silencer ... Kit for a complete transfection optimization , solution ...
    Cached Biology Technology:Assessing Gene Function with siRNA Libraries 2Assessing Gene Function with siRNA Libraries 3Assessing Gene Function with siRNA Libraries 4Assessing Gene Function with siRNA Libraries 5Assessing Gene Function with siRNA Libraries 6Assessing Gene Function with siRNA Libraries 7Ambion Offers Gene Expression Profiling Service 2Ambion Offers Gene Expression Profiling Service 3A New Way to Assess siRNA Delivery Efficiency 2A New Way to Assess siRNA Delivery Efficiency 3A New Way to Assess siRNA Delivery Efficiency 4A New Way to Assess siRNA Delivery Efficiency 5
    (Date:7/31/2015)... , 31 de julio de 2015 ... (ICG-10,  www.icg-10.org ) del 22 al 25 de octubre ... La conferencia celebra su décimo aniversario este ... convertido en una de las reuniones anuales más influyentes ... es una de las conferencias científicas más dinámicas, entusiastas ...
    (Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
    (Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik ... und findet vom 22. bis 25. Oktober 2015 ... Die Konferenz feiert in diesem ... ist die ICG weltweit zu einem der einflussreichsten ... eines der dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
    Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
    ... - FEBS Letters, one of the leading journals for ... new enhancement to the journal article: Structured Digital Abstracts ... Letters is an extension of the regular journal article ... which contains a relationship between two biological entities, mentioning ...
    ... 2, 2008) Autism Speaks, the nations largest autism ... Science and one of the countrys leading autism researchers ... will examine the architecture of the autistic brain. Led ... University of California, San Diego, School of Medicine and ...
    ... premier forum for health care executives to explore a ... leaders. The 2008 Congress will include senior executives and ... systems, health plans, pharmaceutical and biotech companies, and government. ... Health Care Agenda, will feature key health care advisors ...
    Cached Biology News:FEBS Letters Structured Digital Abstracts experiment 2Autism Speaks collaborates on grant with the Allen Institute for Brain Science and autism expert 2Autism Speaks collaborates on grant with the Allen Institute for Brain Science and autism expert 35th Annual World Health Care Congress April 21-23, Washington, D.C. 2
    ... The Aquarius 384 is a compact ... 384-well head is a unique flow-through ... using the included wash system. ... microplate stacker system. Will be ...
    ... 'SoftLinx software, a multitasking application capable ... the programming and operation of lab automation ... enough for custom modification by programmers. ... a simple drag-anddrop flowchart. If you can ...
    ... laboratory's requirements for data management and quality control. ... ... ... software for Staccato Systems and custom Allegro Modules allowing for the simple interface with more than ...
    ... is an integrated digital microscope and camera ... equipment setup, optical adjustment or software installation. ... technology, COOLSCOPE combines simplicity and advanced technology ... offers simultaneous viewing of a macro image ...
    Biology Products: